natgillin/translations-raw huggingface dataset:
In the case of concomitant antiviral therapy for hepatitis B or C, please refer also to the relevant product information for these medicinal products. 
U slučaju istodobne antivirusne terapije za hepatitis B ili C,
Nevirapine AUC ↑ 1.20 
Nevirapin AUC ↑ 1,26
In a mass balance/excretion study in eight healthy male volunteers dosed to steady state with nevirapine 200 mg given twice daily followed by a single 50 mg dose of 14C-nevirapine, approximately 91.4 ± 10.5 % of the radiolabelled dose was recovered, with urine (81.3 ± 11.1 %) representing the primary route of excretion compared to faeces (10.1 ± 1.5%). 
U studiji na osam zdravih muških dobrovoljaca koji su primali nevirapin 200 mg dvaput dnevno do stanja dinamičke ravnoteže, a zatim su primili jednokratnu dozu od 50 mg 14C-nevirapina, povrat radioaktivnosti iznosio je otprilike
Hepatic impairment 
- anafilaktičkog šoka
Adefovir did not influence any of the common CYP isoforms known to be involved in human drug metabolism and is excreted renally. 
CYP izoformi za koje se zna da su uključene u metabolizam lijeka u ljudi te se izlučuje renalnim putem.
Amprenavir Cmin ↓ 0.81 (0.69-0.96) Amprenavir Cmax ↔ 0.97 (0.85-1.10) 
Amprenavir AUC ↔ 0,89 (0,77-1,03) Amprenavir Cmin ↓ 0,81 (0,69-0,96) Amprenavir Cmax ↔ 0,97 (0,85-1,10)
Uncommon Stevens-Johnson syndrome/toxic epidermal necrolysis (which may be fatal) 
Manje često Stevens-Johnsonov sindrom/toksična epidermalna nekroliza (koji mogu biti fatalni) (0,2%), angioedem, urtikarija
Microcrystalline cellulose Lactose (as monohydrate) Povidone K25 
- Pomoćne tvari su mikrokristalična celuloza, laktoza ( u obliku hidrata), povidon
There is not enough evidence to substantiate that the absence of an increased risk for toxicity seen in pretreated women initiating nevirapine with an undetectable viral load (less than 50 copies/ml of HIV-1 in plasma) and CD4 cell counts above 250 cells/mm3 also applies to pregnant women. 
Nema dovoljno dokaza za zaključak da je odsutnost povećanog rizika toksičnosti viđen u prethodno liječenih žena na početku primjene nevirapina, s nedektabilnim virusnim opterećenjem (manje od 50 kopija
Rashes occur alone or in the context of drug reaction with eosinophilia and systemic symptoms, characterised by rash with constitutional symptoms such as fever, arthralgia, myalgia and lympadenopathy, plus visceral involvement, such as hepatitis, eosinophilia, granulocytopenia, and renal dysfunction. 
Osip se pojavljuje samostalno ili u sklopu reakcije na lijek uz eozinofiliju i sistemske simptome, poput, vrućice, artralgije, mijalgije i limpadenopatije, te visceralne poremećaje,
It is not recommended to coadminister atazanavir/ritonavir and Nevirapine Teva (see section 
Ne preporučuje se istodobna primjena atazanavir/ritonavira i Nevirapina Teva (vidjeti dio 4.4).
Very common rash (12.5 %) 
Poremećaji kože i potkožnog tkiva Vrlo često osip (12,5%)
Common (may affect up to 1 in 10 people): - decreased numbers of white blood cells (granulocytopenia) - allergic reactions (hypersensitivity) - headache - feeling sick (nausea) - vomiting - abdominal pain - loose stools (diarrhoea) - inflammation of the liver (hepatitis) - feeling tired (fatigue) - fever - abnormal liver function tests 
Često (mogu se javiti do 1 od 10 osoba): - smanjenje broja bijelih krvnih stanica (granulocitopenija) - alergijske reakcije (preosjetljivost) - glavobolja
Fluconazole 200 mg QD 
Flukonazol 200 mg 1x/dan
Lopinavir Cmin ↓ 0.45 (0.25-0.82) Lopinavir Cmax ↓ 0.86 (0.64-1.16) 
Lopinavir AUC ↓ 0,78 (0,56-1,09) Lopinavir Cmin ↓ 0,45 (0,25-0,82) Lopinavir Cmax ↓ 0,86 (0,64-1,16)
Sodium starch glycolate (Type A) Colloidal silicon dioxide Magnesium stearate 
K25, natrijev škroboglikolat (Vrste A), koloidni silicijev dioksid i magnezijev stearat.
Monotherapy with nevirapine has been associated with the development of NNRTI resistance. 
Teva je povezana s razvojem rezistencije na NNRTI.
If you experience severe rash or hypersensitivity (allergic reactions that may appear in the form of rash) accompanied by other side effects such as - fever, - blistering, - mouth sores, - inflammation of the eye, - swelling of the face, - general swelling, - shortness of breath, - muscle or joint pain, - general feelings of illness, - or abdominal pain 
Ako dobijete teški osip ili preosjetljivost (alergijske reakcije koje se mogu pojaviti u obliku osipa) popraćene drugim nuspojavama kao što su - vrućica, - pojava mjehurića,
Nevirapine Cmax ↑ 1.20 
Nevirapin AUC ↑ 1,20 Nevirapin Cmax ↑ 1,20
Nevirapine Cmin ↑ 1.34 (1.21-1.49) Nevirapine Cmax ↑ 1.25 (1.14-1.37) 
Nevirapin AUC ↑ 1,29 (1,19-1,40) Nevirapin Cmin ↑ 1,34 (1,21-1,49) Nevirapin Cmax ↑ 1,25 (1,14-1,37)
Rifampicin Cmin ND Rifampicin Cmax ↔ 1.06 (0.91-1.22) 
Rifampicin AUC ↔ 1,11 (0,96-1,28) Rifampicin Cmin NO Rifampicin Cmax ↔ 1,06 (0,91-1,22)
Nevirapine Cmin ↑ 1.47 (1.20-1.82) Nevirapine Cmax ↑ 1.18 (1.02-1.37) 
Nevirapin AUC ↑ 1,27 (1,12-1,44) Nevirapin Cmin ↑ 1,47 (1,20-1,82) Nevirapin Cmax ↑ 1,18 (1,02-1,37)
Lopinavir Cmin ↓ 0.54 (0.28-0.74) Lopinavir Cmax ↓ 0.81 (0.62-0.95) 
Lopinavir AUC ↓ 0,73 (0,53-0,98) Lopinavir Cmin ↓ 0,54 (0,28-0,74) Lopinavir Cmax ↓ 0,81 (0,62-0,95)
NRTIs 
NRTI-i
Musculoskeletal and connective tissue disorders Uncommon arthralgia, myalgia 
Manje često artralgija, mijalgija
Renal dysfunction: The single-dose pharmacokinetics of nevirapine has been compared in 23 patients with either mild (50 ≤ CLcr < 80 ml/min), moderate (30 ≤ CLcr < 50 ml/min) or severe renal dysfunction (CLcr < 30 ml/min), renal impairment or end-stage renal disease (ESRD) requiring dialysis, and 8 patients with normal renal function (CLcr > 80 ml/min). 
CLcr, >80 ml/min) (n=8), bolesnici s blagom (50≤ CLcr <80ml/min), umjerenom (30 ≤ CLcr
Nevirapine had a median EC50 value (50% inhibitory concentration) of 63 nM against a panel of group M HIV-1 isolates from clades A, B, C, D, F, G, and H, and circulating recombinant forms (CRF), CRF01_AE, CRF02_AG and CRF12_BF replicating in human embryonic kidney 293 cells. 
HIV-1 niza izolata skupine M podtipova A, B, C, D, F, G, i H te cirkulirajućih rekombinantnih oblika
Didanosine Cmin ND Didanosine Cmax ↔ 0.98 (0.79-1.21) 
Didanozin AUC ↔ 1,08 (0,92-1,27) Didanozin Cmin NO Didanozin Cmax ↔ 0,98 (0,79-1,21)
Ketoconazole Cmax ↓ 0.56 (0.42 
Itrakonazol Cmax ↓ 0,62
Herbal preparations containing St. John‘s Wort and Nevirapine Teva must not be co-administered (see section 4.3). 
Biljni pripravci koji sadrže gospinu travu i Nevirapin Teva ne smiju se primjenjivati istodobno (vidjeti dio
Hypersensitivity (anaphylactic reaction, angioedema and urticaria) have been reported. 
Prijavljeni su slučajevi preosjetljivosti (anafilaktička reakcija,
Saquinavir/ritonavir and Nevirapine Teva can be coadministered without dose adjustments. 
Fosamprenavir/ritonavir i Nevirapin Teva mogu se primjenjivati istodobno bez prilagodbe doze.
- abdominal pain 
- gubitak apetita
For patients who are unable to swallow tablets or who weigh less than 50 kg or whose body surface area is below 1.25 m2 
- čija je površina tijela veća od 1,25 kvadratnih metara Kod djece mlađe od 16 godina, tjelesne mase manje od 50 kg ili površine tijela manje od 1,25
(women more than 250 cells/mm³, men more than 400 cells/mm³) - pre-treated patients with detectable HIV-1 plasma viral load and higher CD4 cell counts at the start of nevirapine therapy (women more than 250 cells/mm³, men more than 400 cells/mm³) 
- osobe s poremećenim rezultatima testova jetrene funkcije - bolesnici prethodno neliječeni antiretrovirusnim lijekovima, s povišenim brojem CD4 stanica na početku terapije Nevirapinom Teva (žene s više od 250 stanica/mm3, muškarci s više od 400 stanica/mm3)
Rifabutin and Nevirapine Teva can be coadministered without dose adjustments. 
Rifabutin i Nevirapin Teva mogu se istodobno primjenjivati bez prilagodbe doze.
Tenofovir and Nevirapine Teva can be co-administered without dose adjustments. 
Tenofovir i Nevirapin Teva mogu se istodobno primjenjivati bez prilagodbe doze.
Nevirapine Teva and emtricitabine may be co-administered without dose adjustments. 
Nevirapin Teva i emtricitabin se mogu istodobno primjenjivati bez prilagodbe doze.
The opposite side is debossed with a scoreline. 
Na drugoj strani tablete nalazi se samo utisnuta razdjelna crta.
Raltegravir and Nevirapine Teva can be co-administered without dose adjustments. 
Raltegravir i Nevirapin Teva mogu se istodobno primjenjivati bez prilagodbe doze.
Fosamprenavir 1,400 mg BID 
Fosamprenavir 1400 mg 2x/dan,
Stavudine Cmin ND Stavudine Cmax ↔ 0.94 (0.86-1.03) 
Stavudin AUC ↔ 0,96 (0,89-1,03) Stavudin Cmin NO Stavudin Cmax ↔ 0,94 (0,86-1,03)
Telbivudine is not a substrate, inducer or inhibitor of the cytochrome P450 (CYP450) enzyme system. 
Telbivudin nije supstrat, induktor niti inhibitor enzimskog sustava citokroma
Methadone Cmin ND Methadone Cmax ↓ 0.58 (0.50 - 0.67) 
Metadon AUC ↓ 0,40 (0,31 - 0,51) Metadon Cmin NO Metadon Cmax ↓ 0,58 (0,50 - 0,67)
Nevirapine Cmin ↑ 1.22 (1.10-1.35) Nevirapine Cmax ↑ 1.13 (1.03-1.24) 
Nevirapin AUC ↑ 1,14 (1,05-1,24) Nevirapin Cmin ↑ 1,22 (1,10-1,35) Nevirapin Cmax ↑ 1,13 (1,03-1,24)
Nevirapine AUC ↑ 1.14 (1.05-1.24) 
Nevirapin Cmax ↑ 1,17 (1,09-1,25)
Name and address of the manufacturers responsible for batch release 
PROIZVOĐAČI ODGOVORNI ZA ZA PUŠTANJE SERIJE LIJEKA U PROMET Ime i adresa proizvođača odgovornih za puštanje serije lijeka u promet
The dose of Nevirapine Teva may need adjusting. 
Nakon prekida uzimanja gospine trave razine nevirapina mogu se povisiti pa može biti potrebna prilagodbe doze Nevirapina Teva.
Uncommon (may affect up to 1 in 100 people): - allergic reaction characterised by rash, swelling of the face, difficulty breathing (bronchial spasm) 
- alergijska reakcija koju karakteriziraju osip, oticanje lica, problemi pri disanju (bronhospazam)
Tipranavir and Nevirapine Teva can be co-administered without dose adjustments. 
Tipranavir i Nevirapin Teva mogu se istodobno primjenjivati bez prilagodbe doze.
Didanosine and Nevirapine Teva can be co-administered without dose adjustments. 
Didanozin i Nevirapin Teva mogu se istodobno primjenjivati bez prilagodbe doze.
anaphylactic reaction, angioedema, urticaria) Uncommon anaphylactic reaction Rare drug reaction with eosinophilia and systemic symptoms Nervous system disorders 
Rijetko reakcija na lijek uz eozinofiliju i sistemske simptome
Co-administration of Nevirapine Teva with elvitegravir in combination with cobicistat is not recommended (see section 4.4). 
Istodobna primjena Nevirapina Teva s elvitegravirom u kombinaciji s kobicistatom se ne preporučuje
If a hypersensitivity reaction occurs, characterised by rash with constitutional symptoms such as fever, arthralgia, myalgia and lymphadenopathy, plus visceral involvement, such as hepatitis, eosinophilia, granulocytopenia, and renal dysfunction, nevirapine must be permanently stopped and not be reintroduced (see section 4.3). 
Ako dođe do pojave reakcije preosjetljivosti, karakterizirane osipom s općim simptomima kao što su vrućica, artralgija, mijalgija i limfadenopatija, uz visceralne poremećaje, kao što su hepatitis,
Common headache 
- općeniti osjećaj bolesti
However, patients with ESRD requiring dialysis exhibited a 43.5 % reduction in nevirapine AUC over a one-week exposure period. 
Međutim, u bolesnika s terminalnom bubrežnom bolešću koja zahtijeva dijalizu tijekom jednotjednog ekspozicijskog razdoblja AUC
DMPA and Nevirapine Teva can be coadministered without dose adjustments. 
DMPA i Nevirapin Teva mogu se istodobno primjenjivati bez prilagodbe doze.
Nevirapine has been evaluated in both treatment-naïve and treatment-experienced patients. 
Nevirapin je ispitivan i u liječenju prethodno neliječenih bolesnika i u liječenju bolesnika prethodno liječenih drugim anti-HIV lijekovima.
Darunavir and Nevirapine Teva can be co-administered without dose adjustments. 
Darunavir i Nevirapin Teva mogu se istodobno primjenjivati bez prilagodbe doze.
Adefovir and Nevirapine Teva may be co-administered without dose adjustments. 
Adefovir i Nevirapin Teva se mogu istodobno primjenjivati bez prilagodbe doze.
Maraviroc and Nevirapine Teva can be co-administered without dose adjustments. 
Maravirok i Nevirapin Teva mogu se istodobno primjenjivati bez prilagodbe doze.
Cimetidine and Nevirapine Teva can be co-administered without dose adjustments. 
Cimetidin i Nevirapin Teva mogu se istodobno primjenjivati bez prilagodbe doze.
Lamivudine and Nevirapine Teva can be co-administered without dose adjustments. 
Lamivudin i Nevirapin Teva se mogu istodobno primjenjivati bez prilagodbe doze.
- muscle or joint pain - general feelings of illness - abdominal pain - hypersensitivity (allergic) reactions - inflammation of the liver (hepatitis) - if you have severe liver disease - if you have had to stop nevirapine treatment in the past because of changes in your liver function - if you are taking a medicine containing the herbal substance St John's Wort (Hypericum perforatum). 
- bol u trbuhu - reakcije preosjetljivosti (alergijske reakcije) - upala jetre (hepatitis) - ako imate tešku bolest jetre
Telbivudine and Nevirapine Teva may be co-administered without dose adjustments. 
Telbivudin i Nevirapin Teva se mogu istodobno primjenjivati bez prilagodbe doze.
Ribavirin and Nevirapine Teva may be co-administered without dose adjustments. 
Ribavirin i Nevirapin Teva se mogu istodobno primjenjivati bez prilagodbe doze.
Ritonavir and Nevirapine Teva can be co-administered without dose adjustments. 
Ritonavir i Nevirapin Teva mogu se istodobno primjenjivati bez prilagodbe doze.
If you notice any of these symptoms please inform your doctor. 
Ukoliko primijetite bilo koji od ovih simptoma,
Stavudine and Nevirapine Teva can be co-administered without dose adjustments. 
Stavudin i Nevirapin Teva mogu se istodobno primjenjivati bez prilagodbe doze.
Nevirapine Teva and abacavir may be co-administered without dose adjustments. 
Nevirapin Teva i abakavir se mogu istodobno primjenjivati bez prilagodbe doze.
Gastrointestinal disorders Common nausea, vomiting, abdominal pain, diarrhoea Hepatobiliary disorders Common hepatitis (including severe and life-threatening hepatotoxicity) (1.9%) Uncommon jaundice 
Često hepatitis (uključujući tešku i po život opasnu hepatotoksičnost) (1,9%) Manje često žutica
EXPIRY DATE 
Rezultati DDI
Plasma trough concentrations of boceprevir were decreased when administered with an NNRTI with a similar metabolic pathway as nevirapine. 
NNRTI-om sa sličnim metaboličkim putem kao nevirapin.
Interferons and Nevirapine Teva may be co-administered without dose adjustments. 
Interferoni i Nevirapin Teva se mogu istodobno primjenjivati bez prilagodbe doze.
This herbal substance may stop Nevirapine Teva from working properly. 
- ako uzimate lijekove koji sadrže biljnu tvar gospinu travu (Hypericum perforatum) jer tvari iz ove biljke mogu zaustaviti pravilno djelovanje Nevirapina Teva.
Nevirapine Teva is indicated in combination with other anti-retroviral medicinal products for the treatment of HIV-1 infected adults, adolescents, and children of any age (see section 4.2). 
infekcije kod odraslih osoba, adolescenata i djece svih dobnih skupina (vidjeti dio 4.2).
You may experience fatigue when taking Nevirapine Teva. 
Tijekom uzimanja Nevirapina Teva možete osjetiti umor.
Patients with severe hepatic impairment (Child-Pugh C) or pre-treatment ASAT or ALAT > 5 ULN until baseline ASAT/ALAT are stabilised < 5 ULN. 
Bolesnici s teškim oštećenjem jetre (Child-Pugh C) ili osobe koje su u fazi prije liječenja imali AST ili
Entecavir and Nevirapine Teva may be co-administered without dose adjustments. 
Entekavir i Nevirapin Teva se mogu istodobno primjenjivati bez prilagodbe doze.
Immune system disorders Common hypersensitivity (incl. 
Manje često anemija Poremećaji imunološkog sustava Često preosjetljivost (uključujući anafilaktičku reakciju, angioedem, urtikariju)
Fluconazole Cmin ↔ 0.93 (0.86-1.01) Fluconazole Cmax ↔ 0.92 (0.85-0.99) 
Flukonazol AUC ↔ 0,94 (0,88-1,01) Flukonazol Cmin ↔ 0,93 (0,86-1,01) Flukonazol Cmax ↔ 0,92 (0,85-0,99) Nevirapin: izloženost ↑100% u usporedbi s povijesnim podacima kada je nevirapin primjenjivan sam.
Enfuvirtide and Nevirapine Teva can be co-administered without dose adjustments. 
Enfuvirtid i Nevirapin Teva mogu se istodobno primjenjivati bez prilagodbe doze.
It is important that you continue taking Nevirapine Teva correctly, as described above, unless your doctor instructs you to stop. 
Stoga, osim ako Vam liječnik nije rekao da prekinete liječenje, važno je nastaviti uzimati Nevirapin Teva na ispravan način, kao što je opisano u prethodnom tekstu.
NET Cmin ND 
Gospina trava
Nevirapine Cmin ↑ 1.32 (1.22-1.43) Nevirapine Cmax ↑ 1.17 (1.09-1.25) 
Nevirapin AUC ↑ 1,25 (1,17-1,34) Nevirapin Cmin ↑ 1,32 (1,22-1,43)
Nevirapine concentrations in human cerebrospinal fluid 
Kombinacije nevirapina s inhibitorima proteaze,
Tell your doctor if you experience any of the following clinical symptoms of liver damage: - loss of appetite - feeling sick (nausea) - vomiting - yellow skin (jaundice) 
Obavijestite liječnika ako primijetite neki od kliničkih simptoma koji upućuju na oštećenje jetre:
Any inflammatory symptoms should be evaluated and treatment instituted when necessary. 
Potrebna je ocjena svih simptoma upale,
according to the Mosteller formula, other nevirapine containing oral formulations are available and should be used if appropriate. 
kvadratnih metara, trebali bi se uzimati drugi dostupni oralni oblici koji sadrže djelatnu tvar nevirapin.
HERBAL PRODUCTS 
BILJNI PRIPRAVCI
Elderly population (≥65 years of age) 
Starija populacija (≥ 65 godina starosti)
DO NOT swallow it whole. 
NEMOJTE ju progutati cijelu.
Maximum tolerated daily dose 
Maksimalna tolerirana dnevna doza
Can't be sold separately. 
Ne smije se zasebno prodavati.
See further information in section 4.4. 
Vidjeti daljnje informacije u dijelu 4.4.
Ask your doctor if you are not sure. 
Upitajte svog liječnika ako niste sigurni.
It may be harmful to the teeth. 
Može štetiti zubima.
- Push the tablet through the aluminium foil. 
- Gurnite tabletu kroz aluminijsku foliju.
- Peel back the paper foil at the corner. 
- Odlijepite papirnatu foliju u kutu.
It is unlikely that this medicine would pass into the mother's milk. 
Mala je vjerojatnost za prelazak ovog lijeka u majčino mlijeko.
The serum phosphorus reduction was maintained over 55 weeks. 
Smanjenje fosfora u serumu održano je tijekom 55 tjedana.
Tablets must be chewed and not swallowed whole; tablets may be crushed. 
Tablete se moraju žvakati, a ne progutati cijele; tablete se smiju drobiti.
Diarrhoea occurred in 11.6% of patients in clinical trials. 
Proljev se pojavio u 11,6% bolesnika u kliničkim ispitivanjima.
- Take the tablet during a meal and chew it (if necessary, the tablet may be crushed to make this easier for you). 
- Uzmite tabletu tijekom obroka i žvačite je (ako je potrebno, tableta se može izdrobiti da bi vam bilo lakše).
Other reproduction toxicity studies showed no adverse effects. 
Ostala ispitivanja reproduktivne toksičnosti nisu pokazala štetne učinke.
After first opening of the bottle the chewable tablets can be used for 90 days. 
Nakon prvog otvaranja boce, tablete za žvakanje mogu se koristiti 90 dana.
Blood levels of radiolabelled iron were very low and confined to the erythrocytes. 
Razine radioaktivno označenoga željeza u krvi bile su vrlo niske i ograničene na eritrocite.
Drug-drug interaction studies have only been performed in healthy volunteers. 
Ispitivanja interakcija među lijekovima provedena su samo na zdravim dobrovoljcima.
In 2 Phase 1 studies, it was concluded that the potential for iron overload is minimal and no dose dependent effects were observed in healthy volunteers. 
U 2 ispitivanja faze 1 zaključeno je da je potencijal za preopterećenje željezom minimalan te da u zdravih dobrovoljaca nisu uočeni učinci ovisni o dozi.
Hypercalcaemia Hypocalcaemia 
Hiperkalcijemija Hipokalcijemija
Do not stop taking the medicine before talking to your doctor or pharmacist as the phosphorus level in your blood may increase (see section 1). 
Nemojte prestati uzimati lijek prije nego što porazgovarate sa svojim liječnikom ili ljekarnikom zbog mogućeg porasta razina fosfora u krvi (pogledajte dio 1.).
Patients are not required to drink more fluid than they normally would. 
Bolesnici ne moraju piti više tekućine nego inače.
Velphoro has been administered to over 248 seniors (≥65 years of age) according to the approved dosing regimen. 
Velphoro je primijenjen u više od 248 starijih osoba (≥ 65 godina starosti), u skladu s odobrenim režimom doziranja.
From week 12 to 24, dose titrations were allowed for both tolerability and efficacy reasons. 
Od 12. tjedna do 24. tjedna bile su dopuštene titracije doze radi utvrđivanja podnošljivosti i djelotvornosti.
For any information about this medicine, please contact the Marketing Authorisation Holder. 
Za sve informacije o ovom lijeku kontaktirajte nositelja odobrenja za stavljanje lijeka u promet.
DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION Date of first authorisation: 26 August 2014 
Datum prvog odobrenja: 26. kolovoza 2014.
If you have missed a dose, just take the next dose at the usual time with a meal. 
Ako ste propustili dozu, jednostavno uzmite sljedeću u uobičajeno vrijeme uz obrok.
Of the total number of subjects in clinical studies of Velphoro, 29.7% were aged 65 and over, while 8.7% were aged 75 and over. 
Od ukupnog broja ispitanika u kliničkim ispitivanjima lijeka Velphoro, njih 29,7% bilo je u dobi od 65 godina i više, dok ih je 8,7% bilo u dobi od 75 godina i više.
The reporting rate is classified as very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1,000 to <1/100). 
Učestalost prijavljivanja klasificirana je kao vrlo često (≥ 1/10), često (≥ 1/100 i < 1/10), manje često (≥ 1/1000 i < 1/100).
Patients receiving Velphoro should adhere to their prescribed diets. 
Bolesnici koji primaju Velphoro trebali bi se pridržavati dijeta koje su im propisane.
If one or more doses are missed, the normal dose of the medicinal product should be resumed with the next meal. 
Ako se propusti jedna ili više doza, uobičajenu dozu lijeka treba nastaviti uz sljedeći obrok.
The distribution studies in humans were not performed. 
Ispitivanja distribucije kod ljudi nisu provedena.
If you are not sure, talk to your doctor before taking this medicine. 
Ako niste sigurni, razgovarajte sa svojim liječnikom prije nego uzmete ovaj lijek.
Subjects were continued on their study medication from week 12 to week 55. 
Ispitanici su nastavili s lijekom primijenjenim u ispitivanju od 12. tjedna do 55. tjedna.
There was no clear evidence of a carcinogenic effect in mice. 
Nije bilo jasnog dokaza za kancerogeni učinak na miševe.
If you are pregnant or breastfeeding, or you think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine. 
Ako ste trudni ili dojite, mislite da biste mogli biti trudni ili planirate imati dijete, obratite se svom liječniku ili ljekarniku za savjet prije nego uzmete ovaj lijek.
The safety and efficacy of Velphoro in children and adolescents below the age of 18 years has not yet been established. 
Sigurnost i djelotvornost lijeka Velphoro u djece i adolescenata mlađih od 18 godina još nije utvrđena.
Therefore Velphoro is not recommended for use in children and adolescents. 
Stoga se Velphoro ne preporučuje za primjenu u djece i adolescenata.
Too much phosphorus in the blood can lead to calcium being deposited in tissues (calcification). 
Previše fosfora u krvi može dovesti do nakupljanja kalcija u tkivima (kalcifikacija).
If you have accidentally taken too many tablets, do not take any more and talk to your doctor or pharmacist immediately. 
Ako ste slučajno uzeli previše tableta, nemojte uzimati nove i odmah se obratite svom liječniku ili ljekarniku.
Only for the blister packs: - Separate the blister pack at perforations. 
Samo za pakiranja s blisterima: - Razdvojite blister pakiranje na perforacijama.
Other medicines and Velphoro 
Drugi lijekovi i Velphoro
This is thought to be most likely an adaptive response to the pharmacological effect of the drug, and not clinically relevant. 
Najvjerojatnije se radi o adaptivnoj reakciji na farmakološki učinak lijeka koja nije klinički relevantna.
Do not take Velphoro: 
Nemojte uzimati Velphoro: